1242 GENETIC VARIATIONS IN REGULATOR OF G-PROTEIN SIGNALING GENES AS SUSCEPTIBILITY LOCI FOR BLADDER CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20111242 GENETIC VARIATIONS IN REGULATOR OF G-PROTEIN SIGNALING GENES AS SUSCEPTIBILITY LOCI FOR BLADDER CANCER Ashish Kamat, Eugene Lee, Yuanqing Ye, and Xifeng Wu Ashish KamatAshish Kamat Houston, TX More articles by this author , Eugene LeeEugene Lee Houston, TX More articles by this author , Yuanqing YeYuanqing Ye Houston, TX More articles by this author , and Xifeng WuXifeng Wu Houston, TX More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.913AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The regulator of G-protein signaling (RGS) is important in normal cellular activity. Recently, alterations in the RGS pathway have been implicated in several human cancers. We hypothesize that alterations in the RGS pathway plays a role in overall bladder cancer risk, recurrence of disease, progression of disease, and overall survival. METHODS This is a case-control study of 803 bladder cancer patients with a matched cohort of 803 normal patients. We evaluated 95 SNPs in 17 RGS genes for overall risk of bladder cancer. Cumulative effect analysis was performed to evaluate the additive risk of unfavorable genotypes. RESULTS Five SNPs showed significant association with overall bladder cancer risk. The most significant SNP was rs10759 located on the RGS4 gene. In an additive genetic model, the variant allele was significantly associated with a 0.77 fold reduced risk of bladder cancer (95% CI 0.66–0.90, P for trend = 0.0007). The association remained statistically significant after adjustment for multiple comparisons. Cumulative effects analysis showed that risk of bladder cancer increased significantly with the number of unfavorable genotypes (P for trend = 1.46×10-6). Compared to patients with 0-1 unfavorable genotypes, the odds ratio for 2-4 unfavorable genotypes was 2.19 (95% CI 1.61–3.00) and the odds ratio for 5 unfavorable genotypes was 4.13 (95% CI 2.14–7.98). CONCLUSIONS Genetic variations in the RGS pathway may infer risk in bladder cancer patients. In the future, this knowledge may lead to bladder cancer risk analysis, prognosis, and modulation. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e497 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ashish Kamat Houston, TX More articles by this author Eugene Lee Houston, TX More articles by this author Yuanqing Ye Houston, TX More articles by this author Xifeng Wu Houston, TX More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...